Drugs / Vesatolimod
Trials 11 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 16 trials | ||||||
| Phase 1 | NCT05458102 | Aug 2022 → May 2023 | HIV infectious disease | Gilead Sciences | Terminated | No outcome recorded |
| Phase 1 | NCT03060447 | May 2017 → Feb 2020 | HIV infectious disease | Gilead Sciences | Completed | No outcome recorded |
| Phase 1 | NCT02858401 | Jan 2015 → Feb 2019 | HIV infectious disease | Gilead Sciences | Completed | No outcome recorded |
| Phase 1 | NCT01590654 | Apr 2012 → Nov 2013 | hepatitis B virus infection | Gilead Sciences | Completed | No outcome recorded |
| Phase 1 | NCT01590641 | Apr 2012 → Sep 2013 | hepatitis B virus infection | Gilead Sciences | Completed | No outcome recorded |
| Phase 1 | NCT01591668 | Mar → Dec 2012 | chronic hepatitis C virus infection | Gilead Sciences | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06071767 | Apr 2024 → Apr 2028 expected | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Recruiting | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT05281510 | Jun 2022 → Jan 2025 | HIV infectious disease | Gilead Sciences | Completed | No outcome recorded |
| Phase 2 | NCT04364035 | Feb 2020 → Oct 2022 | HIV infectious disease | Aelix Therapeutics | Completed | No outcome recorded |
| Phase 2 | NCT02579382 | Nov 2015 → Jan 2017 | chronic hepatitis B virus infection | Gilead Sciences | Completed | No outcome recorded |
| Phase 2 | NCT02166047 | Jun 2014 → May 2016 | chronic hepatitis B virus infection | Gilead Sciences | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2020-03-10 | Gilead Sciences | Treatment With Gilead’s Vesatolimod Is Evaluated for Safety and Virologic and Immunologic Response Versus Placebo in Phase 1B HIV Functional Cure Study gilead.com ↗ |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 14 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Vesatolimod | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03060447 ↗ |
| Known as | GS-9620 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01591668 ↗ |
| Known as | VES | “VRC07523LS + CAP256V2LS + Vesatolimod (VES)” NCT05281510 ↗1“Vesatolimod (VES)” NCT06071767 ↗ |
| Action | Activate | “GS-9620 is a potent oral agonist of toll-like receptor 7” PMID 25105516 ↗ Aug 2014 |
| Modality | Small molecule | — CHEMBL2424780 ↗ |
| Route | Oral | “GS-9620 is a potent oral agonist of toll-like receptor 7” PMID 25105516 ↗ Aug 2014 |
| Target | TLR7 | “Treatment with vesatolimod, an investigational, oral, toll-like receptor 7 (TLR7) agonist, leads to sustained viral remission in some non-human primates when combined with...” PMID 33043969 ↗ Jun 2021 |